A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors

Conclusion The combination of tipifarnib and erlotinib was well tolerated. Erlotinib 150  mg once daily for 28 days combined with tipifarnib 300 mg twice daily for 21 days was identified as the recommended phase 2 dose. Tipifarnib is currently being evaluated inHRAS mutant tumors, providing a potential opportunity to further test this combination.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research